• Publications
  • Influence
Multiple sclerosis.
Multiple sclerosis is the prototype inflammatory autoimmune disorder of the central nervous system and, with a lifetime risk of one in 400, potentially the most common cause of neurologicalExpand
  • 882
  • 84
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assessExpand
  • 863
  • 71
  • PDF
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safetyExpand
  • 853
  • 55
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
BACKGROUND Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. METHODS In this phase 2,Expand
  • 863
  • 40
  • PDF
The window of therapeutic opportunity in multiple sclerosis
AbstractFrom 1991–2002, we treated 58 patients with multiple sclerosis (MS) using the humanised monoclonal antibody, Campath–1H, which causes prolonged T lymphocyte depletion. Clinical and surrogateExpand
  • 453
  • 21
Multiple sclerosis
Multiple sclerosis is primarily an inflammatory disorder of the brain and spinal cord in which focal lymphocytic infiltration leads to damage of myelin and axons. Initially, inflammation is transientExpand
  • 236
  • 20
Disease-relevant autoantibodies in first episode schizophrenia
Dear Sirs, Schizophrenia is a common, heterogenous and complex disorder with unknown aetiology [1]. There is established evidence for N-methyl-d-aspartate receptor (NMDAR) hypofunction [2] as aExpand
  • 265
  • 13
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Objectives Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy overExpand
  • 180
  • 13
  • PDF
B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
IntroductionTreatment with alemtuzumab is highly effective in relapsing–remitting multiple sclerosis; however, 30% of patients develop autoimmunity. Alemtuzumab (previously called Campath 1-H)Expand
  • 180
  • 11
  • PDF
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
Significance This paper identifies the mechanism by which patients with multiple sclerosis develop secondary autoimmunity after treatment with the lymphocyte-depleting humanized monoclonal antibodyExpand
  • 141
  • 9
  • PDF
...
1
2
3
4
5
...